Indivior considers US listing after returning to profit
(Sharecast News) - Indivior said it was considering a US listing for its shares as the drugs company swung to an annual profit and predicted strong growth for its Sublocade opioid.
Read moreWed, 15th May 2019 15:41
(Sharecast News) - Indivior said it was considering a US listing for its shares as the drugs company swung to an annual profit and predicted strong growth for its Sublocade opioid.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreUPDATE: Indivior notes robust results for treatment in fentanyl trial
Read moreCORRECT: Indivior notes results for painkiller in fentanyl trial
Read moreIndivior's painkiller demonstrates positive interaction with fentanyl
Read more(Sharecast News) - Pharmaceutical company Indivior hailed the results of a study aimed at assessing the ability of its buprenorphine asset to reduce respiratory depression and apnea associated with the synthetic opioid fentanyl.
Read moreEXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair
Read moreLONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data
Read moreIN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million
Read more(Sharecast News) - Indivior was under the cosh on Wednesday after US alternative asset management firm Scopia Capital sold 20m shares in the opioid addiction treatment maker in a placing.
Read moreLONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest
Read moreIndivior lifts 2021 revenue guidance amid strong Sublocade sales
Read more(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.
Read more(Sharecast News) - The Financial Mail on Sunday's Midas column told readers to buy shares of Light Science Technologies, pointing out the benefits of the company's technology for health, climate and the UK more economy.
Read moreLONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint
Read more